Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 22 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal
| 0.9540 | 52-week high | +69.30% |
| 0.7600 | Previous month high | +34.87% |
| 0.6700 | Previous week high | +18.90% |
| 0.6700 | Previous month low | +18.90% |
| 0.6607 | R3 (classic) | +17.24% |
| 0.6453 | R2 (classic) | +14.52% |
| 0.6300 | Previous day high | +11.80% |
| 0.6207 | R1 (classic) | +10.14% |
| 0.6100 | Previous week low | +8.25% |
| 0.6053 | Pivot | +7.42% |
| 0.5900 | Previous day low | +4.70% |
| 0.5807 | S1 (classic) | +3.05% |
| 0.5653 | S2 (classic) | +0.33% |
| 0.5635 | Price now | |
| 0.5407 | S3 (classic) | −4.05% |
| 0.3630 | 52-week low | −35.58% |
None of the 29 investors followed here reported a position in COCH in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a COCH trade in the reports read so far (1,252 of 1,254; the rest are being read now).
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 28, 2026 | Lucas Brent TChief Executive Officer | Stock Award(Grant) at price 0.60 per share. | 32.9K | $19.68K |
| Feb 11, 2026 | Taylor Glen AlbertBeneficial Owner of more than 10% of a Class of Security | Purchase at price 0.52 per share. | 18.75M | $9.83M |
| Feb 11, 2026 | Kantor Susan J.Director | Purchase at price 0.52 per share. | 96.2K | $50.41K |
| Feb 11, 2026 | Brynelsen Charles RDirector | Purchase at price 0.52 per share. | 1.00M | $524.30K |
| Feb 11, 2026 | Potashnick RobertChief Financial Officer | Purchase at price 0.52 per share. | 212.5K | $111.41K |
| Feb 11, 2026 | Lucas Brent TChief Executive Officer | Purchase at price 0.52 per share. | 62.5K | $32.77K |
| Feb 11, 2026 | Patel Mona ChetanDirector | Purchase at price 0.52 per share. | 312.5K | $163.84K |
| Nov 27, 2025 | Lucas Brent TChief Executive Officer | Stock Award(Grant) at price 0.71 per share. | 18.1K | $12.91K |
| Jun 10, 2025 | Patel Mona ChetanDirector | Purchase at price 1.47 per share. | 2.5K | $3.67K |
| Jun 5, 2025 | Patel Mona ChetanDirector | Purchase at price 1.46 per share. | 10K | $14.60K |
| May 29, 2025 | Lucas Brent TChief Executive Officer | Stock Award(Grant) at price 1.29 - 1.94 per share. | 12.9K | $20.03K |
| May 26, 2025 | Brynelsen Charles RDirector | Purchase at price 1.64 - 1.68 per share. | 50K | $82.40K |
| Dec 19, 2024 | Anzu Spac Gp I L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 1.03M | — |
| Nov 19, 2024 | Patel Mona ChetanDirector | Purchase at price 2.28 per share. | 2.5K | $5.70K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.7 | 11.4 | -8.1 | 2.3 | 3.8 | 12.2 | -15.3 | 8.6 | -6.6 | -17.3 | −14.8% | ||
| 2025 | 16.1 | -17.5 | -5.1 | 9.2 | 7.1 | -6.6 | 2.8 | -15.8 | -36.9 | 3.7 | 4.2 | -21.2 | −53.8% |
| 2024 | -35.9 | 306.0 | -16.8 | 8.4 | -44.2 | -0.4 | -9.3 | 41.1 | 7.6 | -18.5 | -14.0 | -37.3 | −21.0% |
| 2023 | 0.6 | -1.1 | 0.8 | -0.3 | 0.9 | 1.3 | 0.7 | 0.9 | -32.5 | -82.6 | 84.4 | -19.5 | −81.9% |
| 2022 | -0.5 | 0.3 | 0.5 | 0.3 | -0.3 | 0.3 | 0.2 | 0.1 | -0.1 | 0.9 | 0.7 | 0.4 | +2.9% |
| 2021 | -0.7 | 0.5 | -0.8 | 0.2 | 0.4 | 0.3 | 0.0 | 0.0 | −0.1% |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Buy / hold / sell counts